KR102427380B1 - 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료 - Google Patents

경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료 Download PDF

Info

Publication number
KR102427380B1
KR102427380B1 KR1020207002692A KR20207002692A KR102427380B1 KR 102427380 B1 KR102427380 B1 KR 102427380B1 KR 1020207002692 A KR1020207002692 A KR 1020207002692A KR 20207002692 A KR20207002692 A KR 20207002692A KR 102427380 B1 KR102427380 B1 KR 102427380B1
Authority
KR
South Korea
Prior art keywords
dpp
inhibitor
pharmaceutical composition
delete delete
sulfonylurea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207002692A
Other languages
English (en)
Korean (ko)
Other versions
KR102427380B9 (ko
KR20200013100A (ko
Inventor
에파 울리케 그래페-모디
토마스 클라인
미하엘 마르크
한스-위르겐 뵈를레
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41426834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102427380(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Priority to KR1020227025908A priority Critical patent/KR20220110860A/ko
Publication of KR20200013100A publication Critical patent/KR20200013100A/ko
Application granted granted Critical
Publication of KR102427380B1 publication Critical patent/KR102427380B1/ko
Publication of KR102427380B9 publication Critical patent/KR102427380B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/14—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with two methyl radicals in positions 1 and 3 and two methyl radicals in positions 7, 8, or 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
KR1020207002692A 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료 Active KR102427380B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227025908A KR20220110860A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10591908P 2008-10-16 2008-10-16
EP08166829 2008-10-16
EP08166829.5 2008-10-16
US61/105,919 2008-10-16
EP09167304 2009-08-05
EP09167304.6 2009-08-05
KR1020187009095A KR20180035948A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
PCT/EP2009/063511 WO2010043688A1 (en) 2008-10-16 2009-10-15 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187009095A Division KR20180035948A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025908A Division KR20220110860A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Publications (3)

Publication Number Publication Date
KR20200013100A KR20200013100A (ko) 2020-02-05
KR102427380B1 true KR102427380B1 (ko) 2022-08-01
KR102427380B9 KR102427380B9 (ko) 2025-11-13

Family

ID=41426834

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020207002692A Active KR102427380B1 (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020177012224A Ceased KR20170053742A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020247010795A Pending KR20240046643A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020117008561A Ceased KR20110066936A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020227025908A Ceased KR20220110860A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020187009095A Ceased KR20180035948A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020177012224A Ceased KR20170053742A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020247010795A Pending KR20240046643A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020117008561A Ceased KR20110066936A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020227025908A Ceased KR20220110860A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020187009095A Ceased KR20180035948A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Country Status (20)

Country Link
US (3) US20110275561A1 (cg-RX-API-DMAC7.html)
EP (2) EP2349240A1 (cg-RX-API-DMAC7.html)
JP (6) JP2012505859A (cg-RX-API-DMAC7.html)
KR (6) KR102427380B1 (cg-RX-API-DMAC7.html)
CN (3) CN109700814A (cg-RX-API-DMAC7.html)
AR (1) AR073876A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009305419B2 (cg-RX-API-DMAC7.html)
CA (1) CA2738367C (cg-RX-API-DMAC7.html)
CO (1) CO6361917A2 (cg-RX-API-DMAC7.html)
EA (1) EA026810B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11010971A (cg-RX-API-DMAC7.html)
IL (1) IL211370A0 (cg-RX-API-DMAC7.html)
MA (1) MA32872B1 (cg-RX-API-DMAC7.html)
MX (4) MX2011003774A (cg-RX-API-DMAC7.html)
NZ (2) NZ591996A (cg-RX-API-DMAC7.html)
PE (1) PE20110396A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000176A1 (cg-RX-API-DMAC7.html)
TW (1) TWI520738B (cg-RX-API-DMAC7.html)
UY (1) UY32177A (cg-RX-API-DMAC7.html)
WO (1) WO2010043688A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CA2719272C (en) 2008-03-26 2020-08-18 Oramed Ltd. Methods and compositions for oral administration of proteins
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010212867B2 (en) 2009-02-13 2013-05-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
CN117547538A (zh) * 2009-02-13 2024-02-13 勃林格殷格翰国际有限公司 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
KR20130069615A (ko) * 2010-05-05 2013-06-26 베링거 인겔하임 인터내셔날 게엠베하 피오글리타존 및 리나글립틴을 포함하는 약제학적 제형
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
MX2012014247A (es) * 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
AU2016202261B2 (en) * 2010-11-15 2017-11-30 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US20130303554A1 (en) * 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP2854812A1 (en) * 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
EP4364796A3 (en) * 2013-03-15 2024-07-24 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
TWI682931B (zh) * 2015-05-29 2020-01-21 大陸商江蘇天士力帝益藥業有限公司 黃嘌呤衍生物、其藥物組成物、其製劑以及其用途
AU2017278261A1 (en) 2016-06-05 2019-01-31 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
HRP20050157B1 (en) * 2002-08-21 2013-01-31 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines,the production thereof and the use of the same as medicaments
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE60331236D1 (de) * 2003-07-24 2010-03-25 Eswaran Krishnan Iyer Orale zusammensetzungen zur behandlung von diabetes
CA2540741A1 (en) * 2003-10-03 2005-04-14 Takeda Pharmaceutical Company Limited Agent for treating diabetes
JP2005126430A (ja) * 2003-10-03 2005-05-19 Takeda Chem Ind Ltd 糖尿病治療剤
RS50982B (sr) * 2004-02-18 2010-10-31 Boehringer Ingelheim International Gmbh. 8-[3-amino piperidin-1-il]-ksantini, njihovo dobijanje i njihova primena kao dpp-iv inhibitora
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
JP4854511B2 (ja) * 2004-08-26 2012-01-18 武田薬品工業株式会社 糖尿病治療剤
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1966215A1 (en) * 2005-12-23 2008-09-10 Novartis AG Condensed heterocyclic compounds useful as dpp-iv inhibitors
EP2057160A1 (en) * 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20090597A1 (es) * 2007-08-16 2009-06-06 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
GB2465132B (en) * 2007-09-21 2012-06-06 Lupin Ltd Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
BRPI0920699A2 (pt) * 2008-10-16 2020-09-01 Boehringer Ingelheim International Gmbh uso de um inibidor de dpp-4 no tratamento de diabetes em pacientes com controle insuficiente da glicemia apesar de terapia com um fármaco antidiabético oral ou não-oral
CN102753161A (zh) * 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Drugs of the Future, 2008, 33(6), pp.473-477(2008.06.30.) 1부.*
GRAEFE-MODY, U. 외, "The novel DPP-4 inhibitor BI 1356 (proposed tradename ONDERO) and metformin can be safely co-administered without dose adjustment", DiabetesPro, 68th Scientific Sessions, 2008.6., Poster Number 553-P.(2008.06.30.) 1부.*

Also Published As

Publication number Publication date
JP2025029032A (ja) 2025-03-05
JP2022125360A (ja) 2022-08-26
UY32177A (es) 2010-05-31
JP6262023B2 (ja) 2018-01-17
US20110275561A1 (en) 2011-11-10
MA32872B1 (fr) 2011-12-01
CA2738367A1 (en) 2010-04-22
JP2014129393A (ja) 2014-07-10
CN108042543A (zh) 2018-05-18
JP2012505859A (ja) 2012-03-08
EP2349240A1 (en) 2011-08-03
WO2010043688A1 (en) 2010-04-22
EP3150204A3 (en) 2017-06-14
KR102427380B9 (ko) 2025-11-13
IL211370A0 (en) 2011-04-28
TN2011000176A1 (en) 2012-12-17
CA2738367C (en) 2017-04-04
KR20200013100A (ko) 2020-02-05
CN102186466A (zh) 2011-09-14
KR20240046643A (ko) 2024-04-09
AU2009305419B2 (en) 2015-08-27
MX375132B (es) 2025-03-06
AU2009305419A1 (en) 2010-04-22
JP2016164161A (ja) 2016-09-08
EA201100621A1 (ru) 2011-12-30
US20160058769A1 (en) 2016-03-03
CN109700814A (zh) 2019-05-03
TWI520738B (zh) 2016-02-11
MX2020009811A (es) 2020-10-14
AR073876A1 (es) 2010-12-09
JP6811203B2 (ja) 2021-01-13
KR20170053742A (ko) 2017-05-16
MX2022001797A (es) 2022-03-22
PE20110396A1 (es) 2011-07-17
EA026810B1 (ru) 2017-05-31
KR20220110860A (ko) 2022-08-09
KR20180035948A (ko) 2018-04-06
CO6361917A2 (es) 2012-01-20
JP2018131450A (ja) 2018-08-23
US20170368068A1 (en) 2017-12-28
KR20110066936A (ko) 2011-06-17
NZ605207A (en) 2014-07-25
NZ591996A (en) 2013-03-28
ECSP11010971A (es) 2011-05-31
EP3150204A2 (en) 2017-04-05
TW201021802A (en) 2010-06-16
MX2011003774A (es) 2011-05-23

Similar Documents

Publication Publication Date Title
KR102427380B1 (ko) 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
US20220323434A1 (en) Treatment for diabetes in patients inappropriate for metformin therapy
US10034877B2 (en) Treatment for diabetes in patients inappropriate for metformin therapy
JP2012505859A6 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
US11911388B2 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
JP7174020B2 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
US20240148737A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
HK1157649A (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J301 Trial decision

Free format text: TRIAL NUMBER: 2024100001659; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001657; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001655; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001653; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001651; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001649; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001647; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001645; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001643; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001641; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001639; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2024100001636; TRIAL DECISION FOR INVALIDATION REQUESTED 20240605

Effective date: 20250515

Free format text: TRIAL NUMBER: 2023100002223; TRIAL DECISION FOR INVALIDATION REQUESTED 20230628

Effective date: 20250515

Free format text: TRIAL NUMBER: 2023100002220; TRIAL DECISION FOR INVALIDATION REQUESTED 20230628

Effective date: 20250515

Free format text: TRIAL NUMBER: 2023100002195; TRIAL DECISION FOR INVALIDATION REQUESTED 20230626

Effective date: 20250515

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20230626

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023100002195

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240613

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001744

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001659

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001657

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001655

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001653

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001651

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001649

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001647

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001645

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001643

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001641

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001639

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20240605

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100001636

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20230628

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023100002223

Decision date: 20250515

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2427380

Appeal request date: 20230628

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023100002220

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4

T16 Administrative procedure resumed

Free format text: ST27 STATUS EVENT CODE: U-5-5-T10-T16-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

PJ1202 Withdrawal of action (patent court)

St.27 status event code: A-5-5-V10-V13-crt-PJ1202

V13 Appeal inadmissible, rejected or withdrawn

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V13-CRT-PJ1202 (AS PROVIDED BY THE NATIONAL OFFICE)

P19 Errors in documents containing ipogçös decisions corrected

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20251113

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1024273800000

Gazette reference publication date: 20220801